StockData
Seer, Inc. logo

Seer, Inc. (SEER) company profile

SEERNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.46−0.02 (-1.35%)

Close on Nov 17, 2026Market cap $80.84MP/E –Yield 0.00%

About Seer

Laboratory Analytical Instruments, SIC 3826

Seer, Inc. is a life sciences technology company that provides platforms for unbiased, deep, and large-scale proteomic analysis. Its core offering, the Proteograph Product Suite, consists of consumable assays—including the Proteograph ONE assay—an automation instrument such as the SP200, and data analysis software. By utilizing engineered nanoparticle technology, the system enables peptide-level resolution across complex samples without relying on predefined binding epitopes. The company primarily serves researchers in proteomics and genomics across academic institutions, biopharmaceutical companies, biobanks, and clinical research organizations.

The company operates internationally, having served more than 190 customers across over 20 countries. Its primary executive offices and headquarters are located in Redwood City, California.

Summary of the business section of Seer's latest annual report, written by StockData.

Company profile

Company

Legal name
Seer, Inc.
Headquarters
Redwood City, CA
Address
3800 Bridge Parkway, Suite 102 94065
Phone
(650) 453-0000
Website
seer.bio
Employees
124, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, San Francisco, California

Stock & identifiers

Ticker
SEER
Exchange
Nasdaq
IPO date
Dec 4, 2020
Shares outstanding
55M, Aug 5, 2026
Public float
$113.80M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1726445
CUSIP
81578P106
ISIN
US81578P1066
FIGI
BBG00HPLTRR8
Share class FIGI
BBG00HPLTRS7
EIN
82-1153150

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Omid FarokhzadCEO AND CHAIR, Director5,466,202
Charles EndweissVP Financial Planning Analysis250,632
David R. HornPRESIDENT & CFO486,650
Anthony R. BazarkoChief Commercial Officer75,000
Dipchand NisharDirector75,544
Robert LangerDirector821,025
Isaac RoDirector53,375
Terrance McGuireDirector343,636
Nicolas H. Roelofs PHDDirector91,496
Meeta GulyaniDirector124,043

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$3.55M$4.58M$1.12M$10–
FY2023$5.20M-$136.66K$1.41M$9–
FY2022$6.74M-$15.54M$3.87M$25–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Omid Farokhzad
Chief Executive Officer
$619.21K$937.45K$1.42M$397.17K$173.19K$3.55M-32%
David Horn
President and Chief Financial Officer
$525.89K$292.12K$389.25K$218.26K$2.50K$1.43M-2%
Elona Kogan
Former Chief Legal Officer
$286.12K$217.98K$302.70K–$2.50K$809.30K-41%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 4, 2020
Offer price
$19.00
Securities offered
9,210,527
Gross proceeds
$175.00M
Exchange
Nasdaq
First trading day
Dec 4, 2020
First-day close
$56.46+197.2%
Lock-up ends (est.)
Jun 2, 2021

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 124 employees based in North America, the European Union and the United Kingdom.”

Corporate history

Events identified from SEC filings

DateEventDetails
Feb 26, 2026ListingRegistration of securities on an exchange (Form 8-A)
Jul 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 4, 2020IPOInitial public offering priced (424B4 prospectus)
Nov 30, 2020ListingRegistration of securities on an exchange (Form 8-A)
Jan 4, 2018Name changeName changed from Seer Biosciences, Inc. to Seer, Inc.

See a number that looks wrong?